Steroid 5α-Reductase Inhibition by Polymethoxyflavones

    August 2013 in “ 한국응용생명화학회지
    Yong‐ung Kim, Jaehong Han
    Image of study
    TLDR Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
    In the 2013 study, researchers found that certain polymethoxyflavones (PMFs) can inhibit steroid 5α-reductase, an enzyme linked to benign prostatic hyperplasia (BPH) and possibly androgenetic alopecia. Among the PMFs tested, 5-hydroxy-7,4'-dimethoxyflavone (compound 5) was the most effective, with an IC50 value of 20 µM. The study highlighted the potential of PMFs as non-steroidal treatment options for BPH, noting the importance of specific structural features for their inhibitory activity. The findings suggested that PMFs could be a basis for developing new treatments for BPH and androgenetic alopecia, warranting further research. The study was funded by the National Research Foundation of Korea.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 502 results

      community Detailed 6 months update for FUE HT and 4 years of FIN-MIN journey

      in Progress Pictures  194 upvotes 1 year ago
      A 25-year-old who has been using minoxidil and finasteride for 4 years to treat hair loss, underwent a successful FUE hair transplant in Mumbai, India, in April 2023. The user reported positive results, including increased hair density and reduced frizziness, and plans to continue treatment for further growth.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Similar Research

    5 / 1000+ results